Authors
Fedyk O.V., Sarzhevsky V.A., Melnichenko V.Y., Dubinina U.N., Mochkin N.E., Smirnova E.G., Kolesnikova D.S., Bannikova A.E.
National Medical — Surgical Centre N.I. Pirogov, Moscow, Russia.
Abstract
103 patients with LD were included in this study. The mobilization of PBSC with only colony-stimulating factors (CSF) was carried out for 91 patients, chemotherapy in combination with CSF — for 12 patients. The concentration of CD34+ in peripheral blood (PB) was studied on the day of the intended cytapheresis. Cytapheresis was commenced when CD34 + concentration had been greater than 0.01×106 cells/ml.
22% of lymphoma patients with indications for high-dose chemotherapy and autoHSCT are “poor mobilizers”. A possible contributing factor to poor mobilization is sex of patients.
Keywords: mobilization of peripheral stem cells, lymphoproliferative diseases, autologous transplantation.
References
1. Motalkina, M.S., Kuleva, S.A., Alekseev, S.M. i dr. Primer uspeshnoj mobilizacii stvolovyh krovetvornyh kletok perifericheskoj krovi s pomoshch’yu pleksiafora i pegfilgrastima u pacientki s nekhodzhkinskoj limfomoj. Sovremennaya onkologiya. 2015; 17(2):
2. Pokrovskaya, O.S. Mekhanizm dejstviya i klinicheskaya effektivnost’ antagonista hemokinovogo receptora CXCR4 pleriksafora pri mobilizacii gemopoeticheskih stvolovyh kletok. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika. 2012; 5(4):
3. Pokrovskaya, O.S. Sistemnye effekty G-KSF pri mobilizacii stvolovyh kletok krovi (SKK) u bol’nyh mnozhestvennoj mielomoj (MM). Klinicheskaya onkogematologiya. XII Rossijskij onkologicheskij kongress “Gemoblastozy”:
4. Filatova, L.V. Osobennosti klinicheskogo techeniya i effektivnosti razlichnyh programm kombinirovannoj himioterapii u bol’nyh s limfomoj Hodzhkina s ekstranodal’nymi porazheniyami. Dissertaciya
5. Giralt, S., Costa, L., Schriber, J., et al. Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. Biol Blood Marrow Transplant. 2014; 20:
6. Kim, J.G., Sohn, S.K., Chae, Y.S. et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin"s lymphoma. Bone Marrow Transplantation. 2007; 40:
7. Lemoli, R.M. New Strategies for Stem Cell Mobilization. Mediterr J Hematol Infect Dis 2012; 4; Open Journal System.
8. Mendrone, A.Jr., Arrais, C.A., Saboya, R., Chamone, Dde A., Dulley, F.L. Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients. Transfus Apher Sci. 2008 Dec;39(3):
9. Oliansky, D.M., Czuczman, M., Fisher, R.I., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidencebased review. Biol Blood Marrow Transplant. 2011;17:
10. Pavone, V., Gaudio, F., Console, G., Vitolo, U., Iacopino, P., Guarini, A., Liso, V., Perrone, T., Liso, A. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006 Apr;37(8):
11. To, L.B., Levesque, J-P., and Herbert, K.E. How I treat patients who mobilize hematopoietic stem cells poorly. BLOOD, 27 OCTOBER 2011 _ VOLUME 118, NUMBER 17 HOWI TREAT POOR HSC MOBILIZERS 4537:
12. Wuchter, P., Ran, D., Bruckner, T. et al. Poor Mobilization of Hematopoietic Stem Cells-Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation. Biol Blood Marrow Transplant 16:
13. Yang, S.M., Chen, H., Chen, Y.H., Zhu, H.H., Zhao, T., Liu, K.Y. The more, the less: age and chemotherapy load are predictive of poor stem cell mobilization in patients with hematologic malignancies. Chin Med J (Engl). 2012 Feb;125(4):
